- Syncope following or before any vaccination as a psychogenic response
- Fever and shivering were more frequent when the 23-valent pneumococcal polysaccharide (PPV23) vaccine was co-administered with SHINGRIX
- Use in special populations such as pregnant or nursing women or pediatrics (<18 years of age) has not been established
- Increased risk of Guillain-Barré syndrome was observed in a post-marketing observational study in individuals 65 years of age or older within 42 days following vaccination (estimated 3 excess cases per million doses administered), with insufficient information available to determine a causal relationship with SHINGRIX
For more information:
Please consult the Product Monograph at gsk.ca/SHINGRIX/PM for important information relating to dosing and administration, adverse reactions and drug interactions which have not been discussed in this piece. To request a Product Monograph, or to report an adverse event, please call 1-800-387-7374.